# Phase 0B EP Audit Addendum — generated from canonical crosswalk

**Module:** Electrophysiology (EP)
**Spec source:** `docs/clinical/CLINICAL_KNOWLEDGE_BASE_v4.0.md` §6.2
**Code source:** `backend/src/ingestion/gaps/gapRuleEngine.ts` (registry=48, evaluator=47, gapsPush=49)
**Crosswalk:** `docs/audit/canonical/EP.crosswalk.json` (auditMethod: rule-body-citation-AUDIT-030D)
**Audit date:** 2026-05-04

## 1. Summary

Electrophysiology has **89 spec gaps** across 11 subcategories. Implementation: **21 DET_OK + 26 PARTIAL + 42 SPEC_ONLY** (any-coverage: 47/89 = 52.8%).

**Tier 1 priority status:** 8 DET_OK + 4 PARTIAL + 3 SPEC_ONLY of 15 T1 gaps (T1 any-coverage: 80.0%).

**Spec-explicit SAFETY-tagged gaps:** 7 total; 6 covered (DET_OK), 1 uncovered. Uncovered SAFETY gaps qualify for Tier S triage queue per §6.3.

---

## 2. Coverage by classification

| Classification | Count | % of total |
|---|---:|---:|
| PRODUCTION_GRADE | 0 | 0.0% |
| DET_OK | 21 | 23.6% |
| PARTIAL_DETECTION | 26 | 29.2% |
| SPEC_ONLY | 42 | 47.2% |
| **Total** | **89** | **100.0%** |

**PRODUCTION_GRADE = 0** is platform-wide; gated on closure of AUDIT-001 P0 (test coverage gap). Per AUDIT_METHODOLOGY.md §3.1, no rule classifies PRODUCTION_GRADE until the platform testing baseline is established.

---

## 3. Coverage by tier

| Tier | Total | DET_OK | PARTIAL | SPEC_ONLY | Any-coverage % |
|------|------:|-------:|--------:|----------:|---------------:|
| **T1** | 15 | 8 | 4 | 3 | 80.0% |
| **T2** | 62 | 13 | 20 | 29 | 53.2% |
| **T3** | 12 | 0 | 2 | 10 | 16.7% |
| **Overall** | **89** | **21** | **26** | **42** | **52.8%** |

---

## 4. Per-subcategory breakdown

| Subcategory | T1/T2/T3 | DET_OK | PARTIAL | SPEC_ONLY | Coverage |
|---|---|---:|---:|---:|---:|
| AF Anticoagulation (13) | 6/6/1 | 3 | 1 | 9 | 30.8% |
| LAAC (5) | 2/3/0 | 1 | 1 | 3 | 40.0% |
| Rhythm Control (11) | 4/6/1 | 5 | 2 | 4 | 63.6% |
| Atrial Tachy/SVT (7) | 1/5/1 | 1 | 5 | 1 | 85.7% |
| VT/ICD (7) | 1/6/0 | 1 | 4 | 2 | 71.4% |
| Channelopathies (11) | 0/6/5 | 3 | 4 | 4 | 63.6% |
| Pacing (9) | 0/9/0 | 1 | 3 | 5 | 44.4% |
| CIED Management (8) | 0/7/1 | 0 | 4 | 4 | 50.0% |
| AAD Safety (8) | 0/8/0 | 5 | 1 | 2 | 75.0% |
| Syncope (6) | 0/4/2 | 1 | 1 | 4 | 33.3% |
| Cardiac Arrest (4) | 1/2/1 | 0 | 0 | 4 | 0.0% |

---

## 4.5 — T1 SPEC_ONLY work items (load-bearing for v2.0 Phase 1)

3 T1 spec gaps with zero implementation. These are the load-bearing v2.0 Phase 1 work items for Electrophysiology.

| GAP-ID | Spec line | Subcategory | Detection Logic (excerpt) | Spec SAFETY | BSW pathway |
|---|---:|---|---|---|---|
| GAP-EP-064 | 315 | AF Anticoagulation | OAC e-prescribed but zero pharmacy fills | — | — |
| GAP-EP-065 | 316 | AF Anticoagulation | Proportion of days covered <80% in past 12mo | — | — |
| GAP-EP-099 | 436 | Cardiac Arrest | Cardiac arrest survivor without TTM protocol documentation | — | — |

---

## 4.6 — EXTRA rules + architectural patterns

**Registry-without-evaluator (1):** registry entries with no matching evaluator block body.

- `gap-ep-anticoag-interruption` (registry line 1931): No evaluator body matched via similarity scoring

**Naming convention mismatches (1):** registry IDs not following `gap-ep-` convention.

- `gap-39-qtc-safety` (line 167): expected prefix `gap-ep-`, got `gap-39-`


---

## 5. Tier 1 priority gaps surfaced

| GAP-ID | Spec line | Class | Rule body cite | Notes |
|---|---:|---|---|---|
| GAP-EP-001 | 311 | DET_OK | `gap-ep-oac-afib` (EP-OAC @4018-4071) | + \| Multiple registry ids cited: gap-ep-oac-afib, gap-ep-af-stroke-risk \| auto-verify: preserved-fro |
| GAP-EP-006 | 312 | DET_OK | `gap-ep-006-dabigatran-renal-safety` (EP-006 @4089-4139) | MANUAL OVERRIDE: AUDIT-032 RESOLVED 2026-05-05 — new SAFETY evaluator block added (this PR) covering |
| GAP-EP-007 | 313 | DET_OK | `gap-vd-6-doac-mechanical-valve` (VD-6 @5500-5524) **[cross-module: VHD]** | MANUAL OVERRIDE: cross-module satisfaction. GAP-EP-007 (DOAC on mechanical valve, CRITICAL SAFETY) i |
| GAP-EP-008 | 314 | PARTIAL_DETECTION | `gap-vd-4-mitral-stenosis` (VD-4 @5444-5464) **[cross-module: VHD]** | (no DOAC + MS contraindication; mitral stenosis logic at 5134+ only covers echo surveillance) \| auto |
| GAP-EP-064 | 315 | SPEC_ONLY | — | — (no pharmacy fill data integration) \| auto-verify: No candidate evaluator block above PARTIAL_MATC |
| GAP-EP-065 | 316 | SPEC_ONLY | — | — (no pharmacy fill data integration) \| auto-verify: No candidate evaluator block above PARTIAL_MATC |
| GAP-EP-011 | 328 | DET_OK | `gap-ep-laac` (EP-LAAC @4201-4229) | line 3979+ \| auto-verify: preserved-from-addendum |
| GAP-EP-012 | 329 | PARTIAL_DETECTION | `gap-ep-laac` (EP-LAAC @4201-4229) | (broad rule, no trigger differentiation) \| auto-verify: preserved-from-addendum |
| GAP-EP-013 | 337 | DET_OK | `gap-ep-early-rhythm` (EP-EARLY-RHYTHM @9500-9522) | line 9129+ \| auto-verify: preserved-from-addendum |
| GAP-EP-014 | 338 | PARTIAL_DETECTION | `gap-ep-ablation` (EP-ABLATION @4236-4259) | line 4014+ \| auto-verify: preserved-from-addendum |
| GAP-EP-017 | 339 | DET_OK | `gap-ep-017-hfref-non-dhp-ccb` (EP-017 @4984-5009) | MANUAL OVERRIDE: AUDIT-033 RESOLVED 2026-05-05 — registry entry gap-ep-017-hfref-non-dhp-ccb added ( |
| GAP-EP-018 | 340 | DET_OK | `gap-ep-subclinical-af` (EP-SUBCLINICAL-AF @7132-7155) | line 6819+ \| auto-verify: preserved-from-addendum |
| GAP-EP-079 | 352 | DET_OK | `gap-ep-079-wpw-af-avn-blocker` (EP-079 @4169-4194) | MANUAL OVERRIDE: AUDIT-031 RESOLVED 2026-05-05 — new CRITICAL evaluator block added (this PR) coveri |
| GAP-EP-086 | 363 | PARTIAL_DETECTION | `gap-ep-vt-ablation` (EP-VT-ABLATION @9533-9555) | line 9162+ (broad VT+ICD trigger, not VT-storm-specific) \| auto-verify: preserved-from-addendum |
| GAP-EP-099 | 436 | SPEC_ONLY | — | — \| auto-verify: No candidate evaluator block above PARTIAL_MATCH |

---

## 6. Implementation notes

### 6.1 — EXTRA rules detail

See §4.6 for EXTRA rules + architectural patterns.

### 6.2 — BSW ROI pathway implications

No T1 SPEC_ONLY gaps carry literal BSW pathway tags in CK v4.0 spec text. Pathway analysis is in the §11.5 sequencing notes (hand-authored) and the cross-module synthesis document.

### 6.3 — Strategic posture

*Strategic posture not yet authored. Set `strategicPosture` field in `EP.crosswalk.json` to populate this section.*

---

## 7. Working hypothesis verdict

**For EP:** Moderate implementation coverage; medication/screening surfaces typically built, procedural surfaces often lighter.

Coverage data: 47/89 any-coverage (52.8%); 21/89 DET_OK only (23.6%); 26 PARTIAL via broad-rule consolidation or partial-trigger match; 42 SPEC_ONLY.

Rules-per-DET_OK efficiency: 48 registry rules / 21 DET_OK = 2.29.

---

## 8. Implications for v2.0

v2.0 Phase 1 (T1 priority) work items for EP:
- **3 T1 SPEC_ONLY** gaps requiring full build (detection + UI + tests)
- **4 T1 PARTIAL** gaps requiring hardening (broad-rule discrimination, missing exclusions, dose-protocol specificity)
- **8 T1 DET_OK** gaps requiring test coverage + UI polish to reach PRODUCTION_GRADE

Cross-module satisfaction (HF Device Therapy → EP CRT/ICD pattern; CAD-027 → PV; etc.) is captured structurally in `ruleBodyCite.evaluatorModule` per AUDIT_METHODOLOGY.md §2.1.C.

---

## 9. Module-specific findings

### Manual classification overrides (8)

Rows where the auto-classifier was wrong and the audit author corrected the classification with explicit reasoning:

- **GAP-EP-006** (T1, DET_OK, `gap-ep-006-dabigatran-renal-safety` (EP-006)): MANUAL OVERRIDE: AUDIT-032 RESOLVED 2026-05-05 — new SAFETY evaluator block added (this PR) covering dabigatran (RxNorm 1037045) + eGFR<30 severe renal impairment per FDA Pradaxa PI + 2023 ACC/AHA AFib Class 3 (Harm) LOE B. Includes structured-data-gap branch for missing eGFR (matches EP-XX-7 LVEF-data-required pattern; preserves harm vector via fail-loud rather than silent default). Closes Tier S queue item.
- **GAP-EP-007** (T1, DET_OK, `gap-vd-6-doac-mechanical-valve` (VD-6) cross-module to VHD): MANUAL OVERRIDE: cross-module satisfaction. GAP-EP-007 (DOAC on mechanical valve, CRITICAL SAFETY) is satisfied by VHD module evaluator VD-6 (gap-vd-6-doac-mechanical-valve, line 5312+) which fires on mechanical valve + DOAC RxNorm with explicit RE-ALIGN trial citation Class 3 Harm. Same clinical rule covers GAP-VHD-005 in VHD module. Auto-classifier picked SH-VALVE-IN-VALVE based on "valve" token similarity — wrong match. Architectural fragility documented at AUDIT-027 expanded scope (single rule satisfies spec gaps in two modules).
- **GAP-EP-017** (T1, DET_OK, `gap-ep-017-hfref-non-dhp-ccb` (EP-017)): MANUAL OVERRIDE: AUDIT-033 RESOLVED 2026-05-05 — registry entry gap-ep-017-hfref-non-dhp-ccb added (this PR); evaluator at line 4797 fires SAFETY gap with Class 3 (Harm) classification when HFrEF + on diltiazem (RxNorm 3443) or verapamil (RxNorm 11170). Closes Tier S queue item. Override pin preserved for stability against auto-classifier similarity scoring drift.
- **GAP-EP-079** (T1, DET_OK, `gap-ep-079-wpw-af-avn-blocker` (EP-079)): MANUAL OVERRIDE: AUDIT-031 RESOLVED 2026-05-05 — new CRITICAL evaluator block added (this PR) covering WPW (I45.6) + AF (I48.x) + AVN blocker (8 beta-blockers + 2 non-DHP CCBs + digoxin ingredient/formulations) per 2023 ACC/AHA/ACCP/HRS AFib Class 3 (Harm) LOE B. Mechanism: AVN blockade removes safety governor on rapid accessory-pathway conduction → fatal VF. Switch recommendation: procainamide (8700, post-AUDIT-042) or amiodarone (703); definitive ablation Class 1. All 14 AVN-blocker RxNorms verified via RxNav per AUDIT_METHODOLOGY.md §16. Closes Tier S queue (final item — queue 1 → 0).
- **GAP-EP-026** (T2, PARTIAL_DETECTION, `gap-ep-lqts-bb` (EP-LQTS-BB)): MANUAL OVERRIDE per EP addendum line 131: GAP-EP-026 (Congenital LQTS QT-drug avoidance) covered by overlapping rules EP-LQTS-BB (line 6906+) and EP-TORSADES (line 7121+). PARTIAL because broad coverage of LQTS+QT-drug scenarios but not specifically the congenital subtype with QT-drug avoidance protocol.
- **GAP-EP-043** (T2, DET_OK, `gap-ep-amiodarone-monitor` (EP-AMIODARONE-MONITOR)): MANUAL OVERRIDE per EP addendum line 177: GAP-EP-043 (Amiodarone TSH monitoring) covered by EP-AMIODARONE-MONITOR evaluator (line 4144+) which combines TSH + LFT monitoring. DET_OK.
- **GAP-EP-044** (T2, DET_OK, `gap-ep-amiodarone-monitor` (EP-AMIODARONE-MONITOR)): MANUAL OVERRIDE per EP addendum line 178: GAP-EP-044 (Amiodarone LFT monitoring) covered by same EP-AMIODARONE-MONITOR evaluator (combined TSH+LFT rule). DET_OK.
- **GAP-EP-045** (T2, PARTIAL_DETECTION, `gap-ep-amiodarone-monitor` (EP-AMIODARONE-MONITOR)): MANUAL OVERRIDE per EP addendum line 179: GAP-EP-045 (Amiodarone baseline PFT/CXR) covered partially by EP-AMIODARONE-MONITOR evaluator. PARTIAL per §3.2.1: combined rule covers TSH/LFT but not PFT/CXR baseline screening that spec specifies.


---

## 10. Cross-references

- `docs/clinical/CLINICAL_KNOWLEDGE_BASE_v4.0.md` §6.2 — spec source
- `backend/src/ingestion/gaps/gapRuleEngine.ts` — code source
- `docs/audit/canonical/EP.crosswalk.json` — canonical crosswalk
- `docs/audit/canonical/EP.spec.json` — canonical spec extract
- `docs/audit/canonical/EP.code.json` — canonical code extract
- `docs/audit/canonical/EP.reconciliation.json` — canonical reconciliation
- `docs/audit/AUDIT_METHODOLOGY.md` — canonical audit methodology contract
- `docs/audit/PHASE_0B_CROSS_MODULE_SYNTHESIS.md` — cross-module synthesis
- `docs/audit/AUDIT_FINDINGS_REGISTER.md` — findings register

---

## 11. Cross-module synthesis (per-module slice)

3 cross-module satisfaction case(s) where EP spec gap is satisfied by an evaluator owned by another module:

| Spec gap | Tier | Class | Owning module | Evaluator block |
|---|---|---|---|---|
| GAP-EP-007 | T1 | DET_OK | VHD | `VD-6` |
| GAP-EP-008 | T1 | PARTIAL_DETECTION | VHD | `VD-4` |
| GAP-EP-028 | T2 | PARTIAL_DETECTION | CAD | `CAD-BETA-BLOCKER` |

### 11.5 — Sequencing notes

*Sequencing notes not yet authored. Set `sequencingNotes` field in `EP.crosswalk.json` to populate.*

---

## 12. Lessons learned

*Lessons learned not yet authored. Set `lessonsLearned` field in `EP.crosswalk.json` to populate.*

---

## 13. Wall-clock empirical entry

Audit method: `rule-body-citation-AUDIT-030D`. Audit date: 2026-05-04.

Per-module wall-clock data lives in `docs/audit/canonical/audit_runs.jsonl` (append-only). Aggregate empirical floor table maintained in AUDIT_METHODOLOGY.md §7.2.

---

## 14. Audit verdict

**EP module: MODERATELY BUILT.**

- 21 DET_OK (23.6%), 26 PARTIAL (29.2%), 42 SPEC_ONLY (47.2%)
- 8/15 T1 priority gaps DET_OK; 3 T1 SPEC_ONLY gaps require v2.0 Phase 1 work
- Audit method: `rule-body-citation-AUDIT-030D`. Generated from canonical crosswalk on 2026-05-04.

---

## 15. Methodology citation appendix

Audit methodology per `docs/audit/AUDIT_METHODOLOGY.md` v1.0. Specifically:
- §2 data model (spec/code/crosswalk artifact triplet)
- §3 classification taxonomy (PRODUCTION_GRADE / DET_OK / PARTIAL_DETECTION / SPEC_ONLY) with §3.2 decision rules + §3.2.1 broad-rule consolidation handling
- §4 citation requirements (AUDIT-030)
- §5 evaluator inventory completeness (AUDIT-030.D, 5 comment patterns)
- §6 SAFETY-tag classification rules + Tier S triage queue inclusion
- §11 addendum markdown template (this document's structure)

This addendum is a **generated artifact** rendered from canonical inputs by `backend/scripts/auditCanonical/renderAddendum.ts`. Hand-editing this markdown is rejected by CI; edit `EP.crosswalk.json` (hand-authored fields: `strategicPosture`, `sequencingNotes`, `lessonsLearned`) and re-render.

*Generated from `docs/audit/canonical/EP.crosswalk.json`.*
